PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal Cancer

Survival Clinical Trial

Official title:

PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03611712
• Other study ID #: PH-CP028
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: February 19, 2019
• Est. completion date: February 2025

Study information

• Verified date: November 2023
• Source: PhytoHealth Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the efficacy of PG2 concurrent with concurrent chemoradiation therapy (CCRT) for relieving fatigue among locally advanced esophageal cancer patients who are under preoperative chemoradiation therapy at curative setting. This study will be designed to compare the fatigue status between two study arms patients under CCRT.

The secondary objective is to assess the efficacy of PG2 to improve the quality of life of patient during CCRT. Also, the investigators try to determine the effect of PG2 on tumor response post CCRT, disease free survival (DFS) and overall survival (OS) of patients by comparing the above outcome between the two study arms.

The mechanism of immunomodulatory of PG2 and tumor response, DFS and OS for patients with esophageal cancer treated with preoperative CCRT concurrent with or without PG2 will be investigated in add-on study.

Description:

It's randomized, open-label study. Locally advanced esophageal cancer patients who give consent to participate in this study and meet all other inclusion and exclusion criteria will be eligible to enroll into this study. The eligible patients will be randomized into one of two study arms: 1) the CCRT- PG2 arm; and 2) the CCRT alone arm. All eligible patients will receive the standard preoperative CCRT during study period and standard surgery 6 weeks after completion of radiation therapy.

The primary objective of this study is to evaluate the efficacy of PG2 concurrent with CCRT for relieving fatigue. Patient's fatigue status will be measured by the BFI-T.

The secondary objective is to assess the efficacy of PG2 to improve the quality of life of patient during CCRT. Patients' quality of life will be assessed by the Functional Assessment of Cancer Therapy- General (FACT-G7 v.4). Patients' appetite will be assessed by VAS appetite score. The effect of PG2 on tumor response post CCRT, DFS and OS of patients will also be evaluated.

Peripheral blood samples and tumor biopsy samples will be collected from all subjects at screening period, during CCRT and post CCRT period to perform Immune biomarker assessment in the add-on study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 48
• Est. completion date: February 2025
• Est. primary completion date: February 3, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients who signed the informed consent form;

• The age of eligible patients should be 20-75 years old;

• Performance status of ECOG 0-1 at time of screening;

• Have Esophageal and esophagogastric junction cancer (non-cervical esophagus);

• Have stage IIB-IIIB locally advanced carcinoma of esophagus;

• Pathologically confirmed primary squamous cell carcinoma of the esophagus;

• Patient must be willing and able to complete fatigue and quality of life questionnaires.

Exclusion Criteria:

• BFI > 7 at time of screening;

• Concomitant malignancy or prior invasive malignancy unless disease free for a minimum of 2 years;

• Medical contraindications to esophagectomy;

• Female patients are pregnant or breast-feeding;

• Have inadequate bone marrow, liver, and renal function

• Uncontrolled systemic disease

• Regular steroid use as determined by investigators;

• Patients take central nervous system stimulators such as Methylphenidate within 30 days before screening;

• Patients have enrolled or have not yet completed other investigational drug trials within 30 days before screening.

• BMI < 16

• Nutrition status SGA rating C.

Related Conditions & MeSH terms

• Cancer-related Fatigue
• Esophageal Neoplasms
• Fatigue
• Survival
• Tumor, Esophageal

Intervention

Drug:
• Astragalus Polysaccharides 500 mg
PG2 Lyo. Injection 500 mg will be given on 1 week before CCRT (Week 1, PG2 Lyo. Injection 500 mg, b.i.w), during CCRT (Week 2-6, PG2 Lyo. Injection 500 mg, t.i.w for 5 weeks), and after CCRT (Week 7-8, PG2 Lyo. Injection 500 mg, t.i.w for 2 weeks)

Locations

Country	Name	City	State
Taiwan	Far Eastern Memorial Hospital	Taipei
Taiwan	Mackay Memorial Hospital	Taipei
Taiwan	Taipei Medical University -Shung Ho Hospital	Taipei
Taiwan	Tri-Service General Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
PhytoHealth Corporation

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fatigue by the Brief Fatigue Inventory-Taiwanese Form	The Brief Fatigue Inventory (BFI) has been shown to have good reliability of fatigue measurement. This instrument consists of a one-page fatigue assessment tool that contains nine items, each measuring the severity of fatigue on a 0-through-10 scale. The first three items assess current level of fatigue, and worst and usual fatigue in the preceding 24 hours. Six items assess the extent to which fatigue has interfered with different aspects of life, such as work or social relations, during the preceding 24 hours. The BFI score is calculated from the mean of completed items.	Through 12 weeks
Secondary	Quality of life by the Functional Assessment of Cancer Therapy-General (FACT-G7 v.4)	FACT-G7, a rapid version of the Functional Assessment of Cancer Therapy-General (FACT-G) which is one of most validated assessment tools to evaluate health related qulaity of life (HRQoL) among cancer patients. It is a 27-item instrument containing four subscales: physical well-being (PWB), functional well-being (FWB), social/family well-being (SWB), and emotional well-being (EWB) on 0-4 scale with a recall period of the past 7 days. The scores of these items must be reversed, and then summed to a total, which is the subscale score. The higher score is presented as the better quality of life.	Through 12 weeks
Secondary	Visual Analog Score for appetite	Visual Analog Score for appetite is a single-item scale will be used to measure by A 10-cm vertical line anchored with the number 0 to indicate "no appetite" and number 10 to indicate "worst possible appetite."	Through 12 weeks
Secondary	Tumor response be evaluated by RECIST 1.1, irRECIST and Pathological response.		Week 11 and Week 12
Secondary	Disease free survival	Disease free survival (DFS) is defined as the time from initiation to relapse or death, whichever occurred first.	2 years after the take-off day of the last patient
Secondary	Overall survival in locally advanced esophageal cancer patients with PG2 treatment under preoperative chemoradiation therapy	Overall survival (OS) is defined as the time from initiation to death of any cause.	2 years after the take-off day of the last patient
Secondary	The change of of biomarkers (inhibitory immune factors, dendritic cells makers, tumor-associated macrophages, immune-regulatory markers and oncogenic-mediated immune markers) will be combined to report the immune profile.		Through 12 weeks